Neurocrine Biosciences reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, the company posted revenues of USD 862.5 million. GAAP other income (expense), net, for Q4 2025 was USD 28.5 million. For the full year 2025, GAAP other income (expense), net, reached USD 86.3 million. Non-GAAP other income, net, was USD 25.7 million for Q4 2025 and USD 90.9 million for the full year 2025. Adjustments to other income included changes in fair values of equity investments and other minor adjustments. Neurocrine Biosciences continued to highlight its portfolio, including products such as INGREZZA and CRENESSITY, and maintained its focus on delivering innovative therapies in collaboration with partners like AbbVie. The company reiterated its commitment to advancing its business and provided financial expectations for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA86078) on February 11, 2026, and is solely responsible for the information contained therein.